* Omnicell Inc reported quarterly adjusted earnings of 56 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 62 cents. The mean expectation of nine analysts for the quarter was for earnings of 40 cents per share. Wall Street expected results to range from 34 cents to 47 cents per share.
* Revenue fell 5.4% to $282.42 million from a year ago; analysts expected $280.45 million.
* Omnicell Inc's reported EPS for the quarter was 19 cents.
* The company reported quarterly net income of $8.63 million.
* Omnicell Inc shares had fallen by 8.0% this quarter and gained 6.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Omnicell Inc is $44.50 This summary was machine generated from LSEG data October 30 at 03:11 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.40 0.56 Beat
Jun. 30 2024 0.14 0.51 Beat
Mar. 31 2024 -0.09 0.03 Beat
Dec. 31 2023 0.15 0.33 Beat
Comments